Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Hepatitis B and C in Prison: Exploring Prevalence, Prevention and Treatment Needs, and Willingness to Receive Vaccination in Italy.

Created on 17 Nov 2026

Authors

Giovanna Paduano, Gabriella Di Giuseppe, Giuseppe Nese, Mariantonietta Pisaturo, Maria Pavia

Published in

Journal of medical virology. Volume 98. Issue 11.

Abstract

This study investigated the prevalence of HBV and HCV, HBV vaccination needs, and willingness to undergo HBV vaccination in people in prison in Italy. A cross-sectional study was conducted (October 2023-March 2024) in three prisons in Southern Italy selected to ensure heterogeneity in terms of population and detention characteristics. New arrivals who were expected to remain at the facility for at least 10 days and subjects already present in the facility were eligible. Participants underwent a face-to-face interview, testing for HBV serological markers (HBsAg, anti-HBc, anti-HBs), and anti-HCV screening using a rapid qualitative test. Current HBV infection was defined as HBsAg positivity, past HBV exposure as anti-HBc positivity with or without anti-HBs positivity, HBV vaccine-induced immunity as isolated anti-HBs positivity, and HCV infection as anti-HCV and HCV-RNA positivity.693 PLP were interviewed and screened for HBV and HCV markers. The prevalence of HBV infections was 2.2%, while 15.6% subjects showed past exposure. HBV infection was significantly higher in those aged 41-50 years (OR = 13.49, 95% CI = 1.62-111.9), whereas it was significantly less likely in Italian incarcerated people (OR = 0.07, 95% CI = 0.02-0.3) and those involved in working activities in prison (OR = 0.19, 95% CI = 0.04-0.97). Only 22.1% were immunized through vaccination, and 60.2% were susceptible to infection. Willingness to receive the HBV vaccine in prison was 40.6% and significantly higher in those with longer detention (OR = 2.69, 95% CI = 1.48-4.89) and who attended day hospital (OR = 1.81, 95% CI = 1.01-3.24). The prevalence of HCV was 3.9%, with almost all HCV positive subjects reporting to receive treatment. HCV infection was significantly more likely in older detained people (OR = 4.32, 95% CI = 1.11-16.78), who reported lifetime drug use (OR = 6.89, 95% CI = 1.49-31.91) and intravenous drug use (OR = 8.23, 95% CI = 3.01-22.49), whereas it was less likely in those experiencing their first detention (OR = 0.17, 95% CI = 0.04-0.76). HBV and HCV still circulate among people in prison at higher rates than the general population. Moreover, HBV and HCV screening, as well as HBV vaccination, are not provided to people in prison on a systematic basis. Integrated, multimodal strategies should be adopted to promote opt-out HBV and HCV screening in people in prison and ensure subsequent HBV vaccination or appropriate treatment.

PMID:
43038324
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement